A Phase 1, Multi-center, Open-label Study of IMGN779 Administered Intravenously in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia

Trial Profile

A Phase 1, Multi-center, Open-label Study of IMGN779 Administered Intravenously in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs IMGN 779 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; First in man
  • Sponsors ImmunoGen
  • Most Recent Events

    • 01 Nov 2017 According to an ImmunoGen media release, updated data evaluating the safety and anti-leukemia activity from the dose escalation phase of this trial will be presented at the American Society of Hematology (ASH) Annual Meeting.
    • 29 Aug 2017 According to an ImmunoGen media release, Jazz Pharmaceuticals plc and ImmunoGen, Inc have entered into a collaboration and option agreement granting Jazz Pharmaceuticals exclusive, worldwide rights to opt into development and commercialization of two early-stage, hematology-related antibody-drug conjugate (ADC) programs.
    • 26 Jun 2017 According to an ImmunoGen media release, data from the study were presented in a poster presentation at the 22nd Congress of the European Hematology Association (EHA) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top